drugset / Trial / NCT03959592
Macular Pigment and Visual Performance in Glaucoma Patients
Phase 1/2
Terminated
8 enrolled
Felipe Medeiros, MD
Heidelberg Engineering GmbH · collabIndustrial Orgánica S.A. de C.V. · collabMacuHealth · collab
RandomizedParallel-groupDouble-blindOther
Summary
The purpose of this study is to determine cross-sectional relationships between macular pigment optical density (MPOD) and visual performance in glaucoma. Additionally, the investigators wish to determine the effect of lutein, zeaxanthin, and mesozeaxanthin supplementation on MPOD and visual performance in glaucoma patients.
Timeline
- Start
- 2019-08-21
- Primary completion
- 2021-11-09
- Completion
- 2021-11-09
Outcome
Outcome not reported
Stopped: “Preliminary analysis showed no benefit of the investigational supplement.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lutein | Other / unclassified | 10 mg | Oral |
| Comparator | Zeaxanthin | Small molecule | 2 mg | Oral |
| Comparator | mesozeaxanthin | Unknown | 10 mg | Oral |